deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05117931

A Study of Amivantamab in People With Esophagogastric Cancer

Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer

Sponsor: Janssen Pharmaceuticals

Conditions Esophagogastric Cancer
Interventions Amivantamab
Updated 15 times since 2021 Last updated: Feb 12, 2026 Started: Dec 2, 2021 Primary completion: Nov 30, 2026 Completion: Nov 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Esophagogastric Cancer and is currently ongoing. Janssen Pharmaceuticals leads this study, which shows 15 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Aug 2025 · 8 months · monthly snapshot~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Dec 2024 — Aug 2025 [monthly]

    Recruiting PHASE2

  4. Oct 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  4. Apr 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  5. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  6. Nov 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  7. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  8. Mar 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  9. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations